Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity
EH Herman, SE Lipshultz, N Rifai, J Zhang, T Papoian… - Cancer research, 1998 - AACR
EH Herman, SE Lipshultz, N Rifai, J Zhang, T Papoian, ZX Yu, K Takeda, VJ Ferrans
Cancer research, 1998•AACRThe release of cardiac troponin T (cTnT) as a biomarker of doxorubicin-induced chronic
cardiac injury was evaluated in the spontaneously hypertensive rat (SHR) model. Elevations
in serum levels of cTnT and decreased immunohistochemical staining of heart sections for
this protein were noted in SHRs treated with cumulative doses of doxorubicin (7 mg/kg) that
induced only minimal histological alterations in myocytes. Concentrations of cTnT were
further elevated, coincident with reduced immunohistochemical staining, in SHRs given 10 …
cardiac injury was evaluated in the spontaneously hypertensive rat (SHR) model. Elevations
in serum levels of cTnT and decreased immunohistochemical staining of heart sections for
this protein were noted in SHRs treated with cumulative doses of doxorubicin (7 mg/kg) that
induced only minimal histological alterations in myocytes. Concentrations of cTnT were
further elevated, coincident with reduced immunohistochemical staining, in SHRs given 10 …
Abstract
The release of cardiac troponin T (cTnT) as a biomarker of doxorubicin-induced chronic cardiac injury was evaluated in the spontaneously hypertensive rat (SHR) model. Elevations in serum levels of cTnT and decreased immunohistochemical staining of heart sections for this protein were noted in SHRs treated with cumulative doses of doxorubicin (7 mg/kg) that induced only minimal histological alterations in myocytes. Concentrations of cTnT were further elevated, coincident with reduced immunohistochemical staining, in SHRs given 10–12 mg/kg doxorubicin.
Thus, monitoring serum levels of cTnT can detect doxorubicin-induced myocyte damage in SHR and may prove useful for the noninvasive evaluation of this toxicity in humans.
AACR